Fractionated stereotactic radiotherapy: an interesting alternative to stereotactic radiosurgery in acromegaly

Kuhn, Emmanuelle; Chanson, Philippe

doi:10.1007/s12020-015-0768-6

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FSRT combines stereotactic localization with fractionated therapy, with small doses being administered over several sessions. The FSRT protocol used in this study involved administering a total dose of 50 Gy in 28 or 25 sessions (5 sessions per week) (23). All patients who underwent SRS were treated with gamma knife, which delivers adequate radiation doses (14–34 Gy) to the tumor in one session (23).…”

Section: Methodsmentioning

confidence: 99%

Machine Learning-Based Radiomics Predicts Radiotherapeutic Response in Patients With Acromegaly

et al. 2019

View full text Add to dashboard Cite

Background: Prediction of radiotherapeutic response before radiotherapy could help determine individual treatment strategies for patients with acromegaly. Objective: To develop and validate a machine-learning-based multiparametric MRI radiomics model to non-invasively predict radiotherapeutic response in patients with acromegaly. Methods: This retrospective study included 57 acromegaly patients who underwent postoperative radiotherapy between January 2008 and January 2016. Manual lesion segmentation and radiomics analysis were performed on each pituitary adenoma, and 1561 radiomics features were extracted from each sequence. A radiomics signature was built with a support vector machine using leave-one-out cross-validation for feature selection. Multivariable logistic regression analysis was used to select appropriate clinicopathological features to construct a clinical model, which was then combined with the radiomics signature to construct a radiomics model. The performance of this radiomic model was assessed using receiver operating characteristics (ROC) analysis and its calibration, discriminating ability, clinical usefulness. Results: At 3-years after radiotherapy, 25 patients had achieved remission and 32 patients had not. The clinical model incorporating seven clinical features had an area under the ROC (AUC) of 0.86 for predicting radiotherapeutic response, and performed better than any single clinical feature. The radiomics signature constructed with six radiomics features had a significantly higher AUC of 0.92. The radiomics model showed good discrimination abilities and calibration, with an AUC of 0.96. Decision curve analysis confirmed the clinical utility of the radiomics model. Conclusion: Using pre-radiotherapy clinical and MRI data, we developed a radiomics model with favorable performance for individualized non-invasive prediction of radiotherapeutic response, which may help in identifying acromegaly patients who are likely to benefit from radiotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%